Advertisement

Current Pain and Headache Reports

, Volume 11, Issue 5, pp 343–351 | Cite as

Sensitization, glutamate, and the link between migraine and fibromyalgia

  • Paola Sarchielli
  • Massimiliano Di Filippo
  • Katiuscia Nardi
  • Paolo Calabresi
Article

Abstract

Recent advances have shed insight on the pathophysiologic mechanisms of fibromyalgia and migraine, especially in the chronic form. A growing body of evidence supports the involvement of peripheral and central sensitization disturbances of pain-related processes underlying both disorders. They involve increased glutamate transmission through interaction with its ionotropic and metabotropic receptors. Few studies supporting the implication of this excitatory amino acid in chronic migraine and primary fibromyalgia demonstrated increased levels of glutamate in the cerebrospinal fluid of affected patients. These findings have implications for future therapies directed against glutamate receptors (in particular, N-methyl-D-aspartate receptors). Limited clinical experience in this regard, although promising, does not exclude additional mechanisms contributing to the maintenance of pain, which can be the target of therapeutic approaches in both disorders.

Keywords

Migraine NMDA Receptor Dorsal Horn Central Sensitization Chronic Migraine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Silberstein SD: Migraine pathophysiology and its clinical implications. Cephalalgia 2004, 24(Suppl 2):2–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Price DD, Staud R: Neurobiology of fibromyalgia syndrome. J Rheumatol Suppl 2005, 75:22–28.PubMedGoogle Scholar
  3. 3.
    Vadivelu N, Sinatra R: Recent advances in elucidating pain mechanisms. Curr Opin Anaesthesiol 2005, 18:540–547.PubMedCrossRefGoogle Scholar
  4. 4.
    Coderre TJ, Katz J: Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. Behav Brain Sci 1997, 20:404–419.PubMedCrossRefGoogle Scholar
  5. 5.
    Melzack R, Coderre TJ, Katz J, Vaccarino AL: Central neuroplasticity and pathological pain. Ann N Y Acad Sci 2001, 933:157–174.PubMedCrossRefGoogle Scholar
  6. 6.
    Woolf CJ: Central sensitization: uncovering the relation between pain and plasticity. Anesthesiology 2007, 106:864–867.PubMedCrossRefGoogle Scholar
  7. 7.
    Herrero JF, Laird JM, Lopez-Garcia JA: Wind-up of spinal cord neurons and pain sensation: much ado about something? Prog Neurobiol 2000, 61:169–203.PubMedCrossRefGoogle Scholar
  8. 8.
    Arendt-Nielsen L, Petersen-Felix S: Wind-up and neuroplasticity: is there a correlation to clinical pain? Eur J Anaesthesiol Suppl 1995, 10:1–7.PubMedGoogle Scholar
  9. 9.
    Li J, Simone DA, Larson AA: Windup leads to characteristics of central sensitization. Pain 1999, 79:75–82.PubMedCrossRefGoogle Scholar
  10. 10.
    Ji RR, Woolf CJ: Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol Dis 2001, 8:1–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Cervero F: Spinal cord mechanisms of hyperalgesia and allodynia: role of peripheral input from nociceptors. Prog Brain Res 1996, 113:413–422.PubMedGoogle Scholar
  12. 12.
    Price DD: Selective activation of A-delta and C nociceptive afferents by different parameters of nociceptive heat stimulation: a tool for analysis of central mechanisms of pain. Pain 1996, 68:1–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Woolf CJ, Salter MW: Neuronal plasticity: increasing the gain in pain. Science 2000, 288:1765–1769.PubMedCrossRefGoogle Scholar
  14. 14.
    Goadsby PJ: Migraine, allodynia, sensitisation and all of that... Eur Neurol 2005, 53(Suppl 1):10–16.PubMedCrossRefGoogle Scholar
  15. 15.
    Meeus M, Nijs J: Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol 2007, 26:465–473.PubMedCrossRefGoogle Scholar
  16. 16.
    Le Goff P: Is fibromyalgia a muscle disorder? Joint Bone Spine 2006, 73:239–242.PubMedCrossRefGoogle Scholar
  17. 17.
    Ruster M, Franke S, Spath M, et al.: Detection of elevated N epsilon-carboxymethyllysine levels in muscular tissue and in serum of patients with fibromyalgia. Scand J Rheumatol 2005, 34:460–463.PubMedCrossRefGoogle Scholar
  18. 18.
    Staud R, Rodriguez ME: Mechanisms of disease: pain in fibromyalgia syndrome. Nat Clin Pract Rheumatol 2006, 2:90–98.PubMedCrossRefGoogle Scholar
  19. 19.
    Arendt-Nielsen L, Graven-Nielsen T: Central sensitization in fibromyalgia and other musculoskeletal disorders. Curr Pain Headache Rep 2003, 7:355–361.PubMedCrossRefGoogle Scholar
  20. 20.
    Hurtig IM, Raak RI, Kendall SA, et al.: Quantitative sensory testing in fibromyalgia patients and in healthy subjects: identification of subgroups. Clin J Pain 2001, 17:316–322.PubMedCrossRefGoogle Scholar
  21. 21.
    Sorensen J, Graven-Nielsen T, Henriksson KG, et al.: Hyperexcitability in fibromyalgia. J Rheumatol 1998, 25:152–155.PubMedGoogle Scholar
  22. 22.
    Desmeules JA, Cedraschi C, Rapiti E, et al.: Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003, 48:1420–1429.PubMedCrossRefGoogle Scholar
  23. 23.
    Petzke F, Clauw DJ, Ambrose K, et al.: Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain 2003, 105:403–413.PubMedCrossRefGoogle Scholar
  24. 24.
    Staud R, Vierck CJ, Cannon RL, et al.: Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001, 91:165–175.PubMedCrossRefGoogle Scholar
  25. 25.
    Price DD, Staud R, Robinson ME, et al.: Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain 2002, 99:49–59.PubMedCrossRefGoogle Scholar
  26. 26.
    Staud R, Cannon RC, Mauderli AP, et al.: Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with fibromyalgia syndrome. Pain 2003, 102:87–95.PubMedCrossRefGoogle Scholar
  27. 27.
    Staud R, Price DD, Robinson ME, et al.: Maintenance of windup of second pain requires less frequent stimulation in fibromyalgia patients compared to normal controls. Pain 2004, 110:689–696.PubMedCrossRefGoogle Scholar
  28. 28.
    Gobel H, Weigle L, Kropp P, Soyka D: Pain sensitivity and pain reactivity of pericranial muscles in migraine and tension-type headache. Cephalalgia 1992, 12:142–151.PubMedCrossRefGoogle Scholar
  29. 29.
    Jensen R, Rasmussen BK, Pedersen B, Olesen J: Muscle tenderness and pressure pain thresholds in headache. A population study. Pain 1993, 52:193–199.PubMedCrossRefGoogle Scholar
  30. 30.
    Strassman AM, Raymond SA, Burstein R: Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996, 384:560–564.PubMedCrossRefGoogle Scholar
  31. 31.
    Burstein R: Deconstructing migraine headache into peripheral and central sensitization. Pain 2001, 89:107–110.PubMedCrossRefGoogle Scholar
  32. 32.
    Burstein R, Yarnitsky D, Goor-Aryeh I, et al.: An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47:614–624.PubMedCrossRefGoogle Scholar
  33. 33.
    Mathew NT, Kailasam J, Seifert T: Clinical recognition of allodynia in migraine. Neurology 2004, 63:848–852.PubMedGoogle Scholar
  34. 34.
    Ashkenazi A, Silberstein S, Jakubowski M, Burstein R: Improved identification of allodynic migraine patients using a questionnaire. Cephalalgia 2007, 27:325–329.PubMedCrossRefGoogle Scholar
  35. 35.
    Kitaj MB, Klink M: Pain thresholds in daily transformed migraine versus episodic migraine headache patients. Headache 2005, 45:992–998.PubMedCrossRefGoogle Scholar
  36. 36.
    Cooke L, Eliasziw M, Becker WJ: Cutaneous allodynia in transformed migraine patients. Headache 2007, 47:531–539.PubMedGoogle Scholar
  37. 37.
    Ashkenazi A, Sholtzow M, Shaw JW, et al.: Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia 2007, 27:111–117.PubMedCrossRefGoogle Scholar
  38. 38.
    Burstein R, Cutrer MF, Yarnitsky D: The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000, 123:1703–1709.PubMedCrossRefGoogle Scholar
  39. 39.
    Burstein R, Jakubowski M: Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004, 55:27–36.PubMedCrossRefGoogle Scholar
  40. 40.
    Levy D, Jakubowski M, Burstein R: Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc. Natl Acad Sci U S A 2004, 101:4274–4279.PubMedCrossRefGoogle Scholar
  41. 41.
    Lainez M: Clinical benefits of early triptan therapy for migraine. Cephalalgia 2004, 24(Suppl 2):24–30.PubMedCrossRefGoogle Scholar
  42. 42.
    Dodick D, Silberstein S: Central sensitization theory of migraine: clinical implications. Headache 2006, 46(Suppl 4):S182–S191.PubMedCrossRefGoogle Scholar
  43. 43.
    Jakubowski M, Levy D, Goor-Aryeh I, et al.: Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005, 45:850–861.PubMedCrossRefGoogle Scholar
  44. 44.
    Liu H, Wang H, Sheng M, et al.: Evidence for presynaptic N-methyl-D-aspartate autoreceptors in the spinal cord dorsal horn. Proc Natl Acad Sci U S A 1994, 91:8383–8387.PubMedCrossRefGoogle Scholar
  45. 45.
    Hwang SJ, Pagliardini S, Rustioni A, Valtschanoff JG: Presynaptic kainate receptors in primary afferents to the superficial laminae of the rat spinal cord. J Comp Neurol 2001, 436:275–289.PubMedCrossRefGoogle Scholar
  46. 46.
    Lu CR, Hwang SJ, Phend KD, et al.: Primary afferent terminals that express presynaptic NR1 in rats are mainly from myelinated, mechanosensitive fibers. J Comp Neurol 2003, 460:191–202.PubMedCrossRefGoogle Scholar
  47. 47.
    Lu CR, Hwang SJ, Phend KD, et al.: Primary afferent terminals in spinal cord express presynaptic AMPA receptors. J Neurosci 2002, 22:9522–9529.PubMedGoogle Scholar
  48. 48.
    Engelman HS, MacDermott AB: Presynaptic ionotropic receptors and control of transmitter release. Nat Rev Neurosci 2004, 5:135–145.PubMedCrossRefGoogle Scholar
  49. 49.
    Kerchner GA, Wang GD, Qiu CS, et al.: Direct presynaptic regulation of GABA/glycine release by kainate receptors in the dorsal horn: an ionotropic mechanism. Neuron 2001, 32:477–488.PubMedCrossRefGoogle Scholar
  50. 50.
    Kerchner GA, Wilding TJ, Huettner JE, Zhuo M: Kainate receptor subunits underlying presynaptic regulation of transmitter release in the dorsal horn. J Neurosci 2002, 22:8010–8017.PubMedGoogle Scholar
  51. 51.
    Wilding TJ, Huettner JE: Functional diversity and developmental changes in rat neuronal kainate receptors. J Physiol 2001, 532:411–421.PubMedCrossRefGoogle Scholar
  52. 52.
    Lee CJ, Bardoni R, Tong CK, et al.: Functional expression of AMPA receptors on central terminals of rat dorsal root ganglion neurons and presynaptic inhibition of glutamate release. Neuron 2002, 35:135–146.PubMedCrossRefGoogle Scholar
  53. 53.
    Lee CJ, Labrakakis C, Joseph DJ, Macdermott AB: Functional similarities and differences of AMPA and kainate receptors expressed by cultured rat sensory neurons. Neuroscience 2004, 129:35–48.PubMedCrossRefGoogle Scholar
  54. 54.
    Bardoni R, Torsney C, Tong CK, et al.: Presynaptic NMDA receptors modulate glutamate release from primary sensory neurons in rat spinal cord dorsal horn. J Neurosci 2004, 24:2744–2781.CrossRefGoogle Scholar
  55. 55.
    Lu CR, Willcockson HH, Phend KD, et al.: Ionotropic glutamate receptors are expressed in GABAergic terminals in the rat superficial dorsal horn. J Comp Neurol 2005, 486:169–178.PubMedCrossRefGoogle Scholar
  56. 56.
    Thompson SW, Woolf CJ, Sivilotti LG: Small-caliber afferent inputs produce a heterosynaptic facilitation of the synaptic responses evoked by primary afferent A-fibers in the neonatal rat spinal cord in vitro. J Neurophysiol 1993, 69:2116–2128.PubMedGoogle Scholar
  57. 57.
    Lu WY, Xiong ZG, Lei S, et al.: G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Nat Neurosci 1999, 2:331–338.PubMedCrossRefGoogle Scholar
  58. 58.
    Mannion RJ, Costigan M, Decosterd I, et al.: Neurotrophins: peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity. Proc Natl Acad Sci U S A 1999, 96:9385–9390.PubMedCrossRefGoogle Scholar
  59. 59.
    Sandkuhler J, Chen JG, Cheng G, Randic M: Low-frequency stimulation of afferent Adelta-fibers induces long-term depression at primary afferent synapses with substantia gelatinosa neurons in the rat. J Neurosci 1997, 17:6483–6491.PubMedGoogle Scholar
  60. 60.
    South SM, Kohno T, Kaspar BK, et al.: A conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces NMDA current and injury-induced pain. J Neurosci 2003, 23:5031–5040.PubMedGoogle Scholar
  61. 61.
    Fang L, Wu J, Lin Q, Willis WD: Calcium-calmodulin-dependent protein kinase II contributes to spinal cord central sensitization. J Neurosci 2002, 22:4196–4204.PubMedGoogle Scholar
  62. 62.
    Garry EM, Moss A, Delaney A, et al.: Neuropathic sensitization of behavioral reflexes and spinal NMDA receptor/CaM kinase II interactions are disrupted in PSD-95 mutant mice. Curr Biol 2003, 13:321–328.PubMedCrossRefGoogle Scholar
  63. 63.
    Ji RR, Baba H, Brenner GJ, Woolf CJ: Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat Neurosci 1999, 2:1114–1119.PubMedCrossRefGoogle Scholar
  64. 64.
    Randic M, Jiang MC, Cerne R: Long-term potentiation and long-term depression of primary afferent neurotransmission in the rat spinal cord. J Neurosci 1993, 13:5228–5241.PubMedGoogle Scholar
  65. 65.
    Mitsikostas DD, Sanchez del Rio M, Waeber C, et al.: The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 1998, 76:239–248.PubMedCrossRefGoogle Scholar
  66. 66.
    Larson AA, Giovengo SL, Russell IJ, Michalek JE: Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000, 87:201–211.PubMedCrossRefGoogle Scholar
  67. 67.
    Gallai V, Alberti A, Gallai B, et al.: Glutamate and nitric oxide pathway in chronic daily headache: evidence from cerebrospinal fluid. Cephalalgia 2003, 23:166–174.PubMedCrossRefGoogle Scholar
  68. 68.
    Sarchielli P, Alberti A, Floridi A, Gallai V: Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology 2001, 57:132–134.PubMedGoogle Scholar
  69. 69.
    Sarchielli P, Gallai V: Nerve growth factor and chronic daily headache: a potential implication for therapy. Expert Rev Neurother 2004, 4:115–127.PubMedCrossRefGoogle Scholar
  70. 70.
    Giovengo SL, Russell IJ, Larson AA: Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999, 26:1564–1569.PubMedGoogle Scholar
  71. 71.
    Sarchielli P, Alberti A, Gallai B, et al.: Brain-derived neurotrophic factor in cerebrospinal fluid of patients with chronic daily headache: relationship with nerve growth factor and glutamate levels. J Headache Pain 2002, 3:129–135.CrossRefGoogle Scholar
  72. 72.
    Pezet S, McMahon SB: Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006, 29:507–538.PubMedCrossRefGoogle Scholar
  73. 73.
    Sarchielli P, Mancini ML, Floridi A, et al.: Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain 2007, In press.Google Scholar
  74. 74.
    Kerr BJ, Bradbury EJ, Bennett DL, et al.: Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. J Neurosci 1999, 19:5138–5148.PubMedGoogle Scholar
  75. 75.
    Merighi A, Carmignoto G, Gobbo S, et al.: Neurotrophins in spinal cord nociceptive pathways. Prog Brain Res 2004, 146:291–321.PubMedCrossRefGoogle Scholar
  76. 76.
    Peres MF, Zukerman E, Senne Soares CA, et al.: Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 2004, 24:735–739.PubMedCrossRefGoogle Scholar
  77. 77.
    Woolf CJ, Thompson SW: The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991, 44:293–299.PubMedCrossRefGoogle Scholar
  78. 78.
    Dickenson AH, Sullivan AF: Differential effects of excitatory amino acid antagonists on dorsal horn nociceptive neurones in the rat. Brain Res 1990, 506:31–39.PubMedCrossRefGoogle Scholar
  79. 79.
    Ren K, Hylden JL, Williams GM, et al.: The effects of a non-competitive NMDA receptor antagonist, MK-801, on behavioural hyperalgesia and dorsal horn neuronal activity in rats with unilateral inflammation. Pain 1992, 50:331–344.PubMedCrossRefGoogle Scholar
  80. 80.
    Ren K, Dubner R: NMDA receptor antagonists attenuate mechanical hyperalgesia in rats with unilateral inflammation of the hindpaw. Neurosci Lett 1993, 163:22–26.PubMedCrossRefGoogle Scholar
  81. 81.
    Ma QP, Woolf CJ: Noxious stimuli induce an N-methyl-D-aspartate receptor-dependent hypersensitivity of the flexion withdrawal reflex to touch: implications for the treatment of mechanical allodynia. Pain 1995, 61:383–390.PubMedCrossRefGoogle Scholar
  82. 82.
    Sorensen J, Bengtsson A, Backman E, et al.: Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 1995, 24:360–365.PubMedGoogle Scholar
  83. 83.
    Henriksson KG, Sorensen J: The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia. Rheum Dis Clin North Am 2002, 28:343–351.PubMedCrossRefGoogle Scholar
  84. 84.
    Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, et al.: Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000, 85:483–491.PubMedCrossRefGoogle Scholar
  85. 85.
    Cohen SP, Verdolin MH, Chang AS, et al.: The intravenous ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients. J Pain 2006, 7:391–398.PubMedCrossRefGoogle Scholar
  86. 86.
    Guedj E, Cammilleri S, Colavolpe C, et al.: Predictive value of brain perfusion SPECT for ketamine response in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging 2007, In press.Google Scholar
  87. 87.
    Wood PB: A reconsideration of the relevance of systemic low-dose ketamine to the pathophysiology of fibromyalgia. J Pain 2006, 7:611–614.PubMedCrossRefGoogle Scholar
  88. 88.
    Staud R, Vierck CJ, Robinson ME, Price DD: Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects. J Pain 2005, 6:323–332.PubMedCrossRefGoogle Scholar
  89. 89.
    Fusco BM, Colantoni O, Giacovazzo M: Alteration of central excitation circuits in chronic headache and analgesic misuse. Headache 1997, 37:486–491.PubMedCrossRefGoogle Scholar
  90. 90.
    Nicolodi M, Sicuteri F: Exploration of NMDA receptors in migraine: therapeutic and theoretic implications. Int J Clin Pharmacol Res 1995, 15:181–189.PubMedGoogle Scholar
  91. 91.
    Nicolodi M, Del Bianco PL, Sicuteri F: Modulation of excitatory amino acids pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drugs abuse. Int J Clin Pharmacol Res 1997, 17:97–100.PubMedGoogle Scholar
  92. 92.
    Nicolodi M, Sicuteri F: Negative modulators of excitatory amino acids in episodic and chronic migraine: preventing and reverting chronic migraine. Special lecture 7th INWIN Congress. Int J Clin Pharmacol Res 1998, 18:93–100.PubMedGoogle Scholar
  93. 93.
    Brown DG, Krupp JJ: N-methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics. Curr Top Med Chem 2006, 6:749–770.PubMedCrossRefGoogle Scholar
  94. 94.
    Gogas KR: Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 2006, 6:68–74.PubMedCrossRefGoogle Scholar
  95. 95.
    Szekely JI, Torok K, Mate G: The role of ionotropic glutamate receptors in nociception with special regard to the AMPA binding sites. Curr Pharm Des 2002, 8:887–912.PubMedCrossRefGoogle Scholar
  96. 96.
    Planells-Cases R, Lerma J, Ferrer-Montiel A: Pharmacological intervention at ionotropic glutamate receptor complexes. Curr Pharm Des 2006, 12:3583–3596.PubMedCrossRefGoogle Scholar
  97. 97.
    Varney MA, Gereau RW: Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. Curr Drug Targets CNS Neurol Disord 2002, 1:283–296.PubMedCrossRefGoogle Scholar
  98. 98.
    Ritzen A, Mathiesen JM, Thomsen C: Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin Pharmacol Toxicol 2005, 97:202–213.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Paola Sarchielli
    • 1
  • Massimiliano Di Filippo
  • Katiuscia Nardi
  • Paolo Calabresi
  1. 1.Neurologic Clinic, Department of Medical and Surgical Specialties and Public HealthUniversity of Perugia, Ospedale Santa Maria della MisericordiaSan SistoItaly

Personalised recommendations